| US 7,572,834 B1 | ||
| Rasagiline formulations and processes for their preparation | ||
| Jeffrey Sterling, Jerusalem (Israel); David Lerner, Jerusalem (Israel); Harel Rosen, Ra'anana (Israel); Leonid Bronov, Netanya (Israel); Dalia Medini-Green, Pardes Hanna (Israel); Berta Iosefzon, Jerusalem (Israel); Tirtsah Berger-Peskin, Ra'anana (Israel); Ramy Lidor-Hadas, Kfar Saba (Israel); and Eliezer Bahar, Tel Aviv (Israel) | ||
| Assigned to Teva Pharmaceutical Industries, Ltd., Petach-Tikva (Israel) | ||
| Filed on Dec. 05, 2006, as Appl. No. 11/634,916. | ||
| Claims priority of provisional application 60/742823, filed on Dec. 06, 2005. | ||
| Int. Cl. A61K 31/135 (2006.01); C07C 211/42 (2006.01) | ||
| U.S. Cl. 514—647 [564/308] | 12 Claims |
1. A pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and
greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure:
 and any salts of the compound,
wherein the compound is formed by chlorination of N-propargyl-1(R)-aminoindan in N-propargyl-1(R)-aminoindan mesylate.
|